William Camu

List of Publications by Year in Descending Order

157 papers	9,167 citations	46 h-index	93 g-index
191 ext. papers	10,520 ext. citations	5.8 avg, IF	5.15 L-index

#	Paper	IF	Citations
157	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.. *Neurology and Therapy*, **2022**, 1	4.6	0
156	Impact of a frequent nearsplice variant in amyotrophic lateral sclerosis: optimising genetic screening for gene therapy opportunities. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 942-949	5.5	0
155	Evidence of mosaicism in SPAST variant carriers in four French families. *European Journal of Human Genetics*, **2021**, 29, 1158-1163	5.3	2
154	Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2021**, 99, 102.e11-102.e20	5.6	8
153	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. *Journal of Neuroradiology*, **2021**, 48, 170-175	3.1	3
152	Effect of familial clustering in the genetic screening of 235 French ALS families. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 479-484	5.5	2
151	Increased worsening of amyotrophic lateral sclerosis patients during Covid-19-related lockdown in France. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 22, 505-507	3.6	6
150	High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families. *Genetics in Medicine*, **2021**, 23, 2160-2170	8.1	2
149	An amyotrophic lateral sclerosis hot spot in the French Alps associated with genotoxic fungi. *Journal of the Neurological Sciences*, **2021**, 427, 117558	3.2	7
148	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. *JAMA Neurology*, **2021**, 78, 1236-1248	17.2	5
147	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Neurology, The*, **2021**, 20, 821-831	24.1	3
146	Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. *Brain Communications*, **2021**, 3, fcab141	4.5	1
145	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. *Brain*, **2021**, 144, 2798-2811	11.2	2
144	Connaître la sclérose latérale amyotrophique pour mieux accompagner les patients. *Actualites Pharmaceutiques*, **2020**, 59, 22-25	0	
143	Prise en charge d'une personne atteinte de sclérose latérale amyotrophique. *Actualites Pharmaceutiques*, **2020**, 59, 26-28	0	
142	Les traitements de la sclérose latérale amyotrophique. *Actualites Pharmaceutiques*, **2020**, 59, 29-33	0	
141	Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort. *Frontiers in Neuroscience*, **2020**, 14, 316	5.1	4

140	Oligogenicity, C9orf72 expansion, and variant severity in ALS. *Neurogenetics*, **2020**, 21, 227-242	3	6
139	Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study. *Frontiers in Neurology*, **2020**, 11, 363	4.1	1
138	High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study. *EClinicalMedicine*, **2020**, 19, 100254	11.3	3
137	Pre-symptomatic diagnosis in ALS. *Revue Neurologique*, **2020**, 176, 166-169	3	3
136	Autosomal dominant SPG9: intrafamilial variability and onset during pregnancy. *Neurological Sciences*, **2020**, 41, 1931-1933	3.5	2
135	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. *Revue Neurologique*, **2020**, 176, 100-112	3	6
134	Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. *EBioMedicine*, **2020**, 59, 102844	8.8	12
133	Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. *European Journal of Neurology*, **2020**, 27, 251-257	6	36
132	ALS and environment: Clues from spatial clustering?. *Revue Neurologique*, **2019**, 175, 652-663	3	15
131	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. *Annals of Neurology*, **2019**, 85, 470-481	9.4	72
130	Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	25
129	An Update on Vitamin D and Disease Activity in Multiple Sclerosis. *CNS Drugs*, **2019**, 33, 1187-1199	6.7	30
128	Theme 4 In vivo experimental models. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 160-187	3.6	0
127	Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6,	9.1	35
126	Phenotypic and genotypic studies of ALS cases in ALS-SMA families. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 432-437	3.6	6
125	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet, The*, **2018**, 391, 1263-1273	40	422
124	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurology, The*, **2018**, 17, 405-415	24.1	150
123	Liver X Receptor Genes Variants Modulate ALS Phenotype. *Molecular Neurobiology*, **2018**, 55, 1959-1965	6.2	20

122	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. *Lancet Neurology, The*, **2018**, 17, 689-698	24.1	34
121	The Use of Peripherally Inserted Central Catheter in Amyotrophic Lateral Sclerosis Patients at a Later Stage. *European Neurology*, **2017**, 77, 87-90	2.1	4
120	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurology, The*, **2017**, 16, 208-216	24.1	36
119	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. *Journal of Autoimmunity*, **2017**, 79, 84-90	15.5	51
118	Adult-onset spinal muscular atrophy: An update. *Revue Neurologique*, **2017**, 173, 308-319	3	12
117	SOD1 mutation can mask C9orf72 abnormal expansion. *European Journal of Neurology*, **2017**, 24, e24	6	1
116	Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 296-297	3.6	0
115	Teriflunomide-induced psoriasiform changes of fingernails: a new example of paradoxical side effect?. *International Journal of Dermatology*, **2017**, 56, 1479-1481	1.7	6
114	Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 519-527	3.6	14
113	KCC3 loss-of-function contributes to Andermann syndrome by inducing activity-dependent neuromuscular junction defects. *Neurobiology of Disease*, **2017**, 106, 35-48	7.5	7
112	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. *Neurology*, **2016**, 87, 2491-2494	6.5	17
111	The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS. *Journal of Neurology*, **2016**, 263, 299-305	5.5	10
110	MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon): A Success Story of the European Innovation Partnership on Active and Healthy Ageing. *Journal of Frailty & Aging,the*, **2016**, 5, 233-241	2.6	5
109	Liver X receptors: from cholesterol regulation to neuroprotection-a new barrier against neurodegeneration in amyotrophic lateral sclerosis?. *Cellular and Molecular Life Sciences*, **2016**, 73, 3801-8	10.3	8
108	Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. *Multiple Sclerosis Journal*, **2015**, 21, 1251-61	5	88
107	A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 490-6	3.6	4
106	Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis. *European Journal of Neurology*, **2015**, 22, 564-9	6	35
105	Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. *Human Molecular Genetics*, **2015**, 24, 1363-73	5.6	98

104	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. *Journal of Medical Genetics*, **2014**, 51, 419-24	5.8	96
103	MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) in Languedoc Roussillon. *European Geriatric Medicine*, **2014**, 5, 406-415	3	16
102	Peripheral myelin protein 22 gene duplication with atypical presentations: a new example of the wide spectrum of Charcot-Marie-Tooth 1A disease. *Neuromuscular Disorders*, **2014**, 24, 524-8	2.9	16
101	Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2014**, 35, 1198-205	5.6	59
100	Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. *BMJ Open*, **2014**, 4, e005528	3	20
99	A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. *European Journal of Neurology*, **2014**, 21, 40-8	6	28
98	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. *JAMA Neurology*, **2014**, 71, 436-41	17.2	110
97	Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. *Current Pharmaceutical Design*, **2014**, 20, 5928-44	3.3	44
96	Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. *Neurobiology of Aging*, **2013**, 34, 1311.e1-2	5.6	30
95	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nature Genetics*, **2013**, 45, 1353-60	36.3	934
94	C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. *Journal of Alzheimer's Disease*, **2013**, 34, 485-99	4.3	80
93	Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. *European Journal of Human Genetics*, **2013**, 21, 237-9	5.3	25
92	A rare motor neuron deleterious missense mutation in the DPYSL3 (CRMP4) gene is associated with ALS. *Human Mutation*, **2013**, 34, 953-60	4.7	26
91	Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. *Human Molecular Genetics*, **2013**, 22, 2350-60	5.6	61
90	Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. *Frontiers in Cellular Neuroscience*, **2013**, 7, 214	6.1	34
89	Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from southern France. *PLoS ONE*, **2013**, 8, e83406	3.7	97
88	Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. *Journal of Medical Genetics*, **2012**, 49, 258-63	5.8	131
87	Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2012**, 33, 839.e1-3	5.6	28

86	Analysis of the SORT1 gene in familial amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2012**, 33, 1845.e7-9	5.6	2
85	UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2012**, 33, 2230.e1-2230.e5	5.6	31
84	Amyotrophic lateral sclerosis: a hormonal condition?. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 585-8		44
83	Lethal multiple sclerosis relapse after natalizumab withdrawal. *Neurology*, **2012**, 79, 2214-6	6.5	50
82	Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*, **2012**, 317, 58-61	3.2	20
81	Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. *European Journal of Human Genetics*, **2012**, 20, 588-91	5.3	16
80	Subcutaneous IFN-β1a to treat´relapsing-remitting multiple sclerosis. *Expert Review of Neurotherapeutics*, **2012**, 12, 1283-91	4.3	
79	C9orf72 hexanucleotide repeat expansions as the causative mutation for chromosome 9p21-linked amyotrophic lateral sclerosis and frontotemporal dementia. *Archives of Neurology*, **2012**, 69, 1159-63		16
78	Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. *Neurology*, **2012**, 78, 1519-26	6.5	47
77	Ipsilateral uveitis and optic neuritis in multiple sclerosis. *Multiple Sclerosis International*, **2012**, 2012, 372361		7
76	Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*, **2011**, 303, 124-7	3.2	27
75	Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2011**, 32, 555.e13-4	5.6	34
74	Screening of OPTN in French familial amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2011**, 32, 557.e11-3	5.6	54
73	APOE ε4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. *European Journal of Neurology*, **2011**, 18, 1046-52	6	15
72	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. *Clinical Immunology*, **2011**, 138, 239-46	9	23
71	Identification of a FUS splicing mutation in a large family with amyotrophic lateral sclerosis. *Journal of Human Genetics*, **2011**, 56, 247-9	4.3	18
70	Identification of novel FUS mutations in sporadic cases of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 113-7		27
69	TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. *Human Molecular Genetics*, **2011**, 20, 1400-10	5.6	265

68	Respiratory onset in an ALS family with L144F SOD1 mutation. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 747-9	5.5	5
67	The P413L chromogranin B variation in French patients with sporadic amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2011**, 12, 210-4		7
66	Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. *Archives of Neurology*, **2011**, 68, 739-42		63
65	Resequencing of 29 candidate genes in patients with familial and sporadic amyotrophic lateral sclerosis. *Archives of Neurology*, **2011**, 68, 587-93		34
64	High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. *Multiple Sclerosis Journal*, **2011**, 17, 720-4	5	16
63	Diabetes insipidus as a first manifestation in multiple sclerosis. *Neurology*, **2011**, 76, 1939-40	6.5	3
62	Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. *Patient Preference and Adherence*, **2010**, 4, 127-33	2.4	4
61	Neuromyelitis optica in France: a multicenter study of 125 patients. *Neurology*, **2010**, 74, 736-42	6.5	171
60	SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. *Journal of Medical Genetics*, **2010**, 47, 554-60	5.8	226
59	Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 572-7	5.5	49
58	Long-term follow-up of neuromyelitis optica with a pediatric onset. *Neurology*, **2010**, 75, 1084-8	6.5	89
57	Questioning on the role of D amino acid oxidase in familial amyotrophic lateral sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, E107; author reply E108	11.5	14
56	Analysis of the UNC13A gene as a risk factor for sporadic amyotrophic lateral sclerosis. *Archives of Neurology*, **2010**, 67, 516-7		24
55	A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. *American Journal of Human Genetics*, **2010**, 86, 77-82	11	162
54	FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. *Journal of Alzheimer's Disease*, **2010**, 22, 765-9	4.3	70
53	Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 21777-82	11.5	44
52	Mutations in FUS cause FALS and SALS in French and French Canadian populations. *Neurology*, **2009**, 73, 1176-9	6.5	110
51	High metabolic level in patients with familial amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2009**, 10, 113-7		99

50	Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. *Neurology*, **2009**, 72, 1669-76	6.5	82
49	TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. *Annals of Neurology*, **2009**, 65, 470-3	9.4	240
48	Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone). *Journal of the European Academy of Dermatology and Venereology*, **2009**, 23, 1332-3	4.6	9
47	A mutation that creates a pseudoexon in SOD1 causes familial ALS. *Annals of Human Genetics*, **2009**, 73, 652-7	2.2	25
46	Association study of the ubiquitin conjugating enzyme gene UBE2H in sporadic ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2009**, 10, 432-5		7
45	The importance of the SMN genes in the genetics of sporadic ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2009**, 10, 436-40		25
44	NOMADMUS : création d'une cohorte française de neuro-optico-myélite aiguë de Devic et des syndromes neurologiques apparentés. *Revue Neurologique*, **2009**, 165, S57-S58	3	
43	Neuromyélite optique de Devic et patients "haut risque" enquête rétrospective nationale. *Revue Neurologique*, **2009**, 165, S55-S56	3	
42	Étude épidémiologique, phénotypique et génétique rétrospective dans une cohorte de 283 familles : un nouvel argument pour la prédominance d'une transmission non monogénique. *Revue Neurologique*, **2009**, 165, S26-S27	3	
41	Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. *Journal of Medical Genetics*, **2009**, 46, 112-4	5.8	138
40	TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nature Genetics*, **2008**, 40, 572-4	36.3	1171
39	Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. *European Journal of Neurology*, **2008**, 15, 1245-51	6	102
38	Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. *Neurology*, **2008**, 71, 514-20	6.5	42
37	Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. *Archives of Neurology*, **2008**, 65, 1333-6		44
36	Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2007**, 13, 941-4	5	13
35	Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. *Archives of Neurology*, **2007**, 64, 240-5		101
34	SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. *Neurology*, **2006**, 67, 1147-50	6.5	71
33	Quelle est la place de l'enquête génétique ?. *Revue Neurologique*, **2006**, 162, 91-95	3	

32	Prise en charge psychologique du patient et de son entourage y compris ˆlong terme. *Revue Neurologique*, **2006**, 162, 295-300	3	2
31	A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. *Journal of Biological Chemistry*, **2004**, 279, 45951-6	5.4	137
30	Etude des gènes SMN dans les maladies du motoneurone de l'adulte. *Revue Neurologique*, **2004**, 160, 10-11	3	
29	A clustering of conjugal amyotrophic lateral sclerosis in southeastern France. *Archives of Neurology*, **2003**, 60, 553-7		37
28	Mutation screening of the ALS2 gene in sporadic and familial amyotrophic lateral sclerosis. *Archives of Neurology*, **2003**, 60, 1768-71		36
27	Absence of mutations in the hypoxia response element of VEGF in ALS. *Muscle and Nerve*, **2003**, 28, 774-5	3.4	25
26	N19S, a new SOD1 mutation in sporadic amyotrophic lateral sclerosis: no evidence for disease causation. *Annals of Neurology*, **2003**, 53, 815-8	9.4	20
25	Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. *Annals of Neurology*, **2002**, 51, 243-6	9.4	83
24	SMN1 gene study in three families in which ALS and spinal muscular atrophy co-exist. *Neurology*, **2002**, 59, 1464-6	6.5	14
23	A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. *American Journal of Human Genetics*, **2002**, 70, 251-6	11	116
22	Motor neuron disease after electric injury. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 71, 265-7	5.5	32
21	Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. *Annals of Neurology*, **2001**, 49, 267-71	9.4	67
20	Monofocal motor neuropathy responsive to intravenous immunoglobulins. *Muscle and Nerve*, **2000**, 23, 1610-1	3.4	11
19	Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country. *European Journal of Neurology*, **2000**, 7, 207-11	6	32
18	Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease?. *Archives of Dermatology*, **2000**, 136, 521-4		38
17	Acute hepatitis after riluzole administration. *Journal of Hepatology*, **1999**, 30, 527-30	13.4	36
16	Genetics of familial ALS and consequences for diagnosis. French ALS Research Group. *Journal of the Neurological Sciences*, **1999**, 165 Suppl 1, S21-6	3.2	56
15	Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease. *Annals of Neurology*, **1998**, 43, 640-4	9.4	60

14	Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. *Human Molecular Genetics*, **1998**, 7, 2045-50	5.6	98
13	Hydrogen peroxide-induced motoneuron apoptosis is prevented by poly ADP ribosyl synthetase inhibitors. *NeuroReport*, **1998**, 9, 1835-8	1.7	33
12	Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. *Canadian Journal of Neurological Sciences*, **1998**, 25, 192-6	1	67
11	Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. *Journal of the Neurological Sciences*, **1996**, 139 Suppl, 34-7	3.2	74
10	Motor evoked potentials (MEPs): evaluation of the different types of responses in amyotrophic lateral sclerosis and primary lateral sclerosis. *Electromyography and Clinical Neurophysiology*, **1996**, 36, 361-8		19
9	Survival of newly postmitotic motoneurons is transiently independent of exogenous trophic support. *Journal of Neuroscience*, **1995**, 15, 3128-37	6.6	27
8	Embryonic rat motoneurons express a functional P-type voltage-dependent calcium channel. *International Journal of Developmental Neuroscience*, **1995**, 13, 429-36	2.7	22
7	Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. *Acta Neurologica Scandinavica*, **1993**, 88, 51-5	3.8	57
6	Purification of Spinal Motoneurons from Chicken and Rat Embryos by Immunopanning. *Methods*, **1993**, 2, 191-199		10
5	Motoneuron survival factors: biological roles and therapeutic potential. *Neuromuscular Disorders*, **1993**, 3, 455-8	2.9	18
4	Neurotrophic factors in development and plasticity of spinal neurons. *Restorative Neurology and Neuroscience*, **1993**, 5, 15-28	2.8	14
3	Neurotrophins promote motor neuron survival and are present in embryonic limb bud. *Nature*, **1993**, 363, 266-70	50.4	562
2	Coexistence of amyotrophic lateral sclerosis and Werdnig-Hoffmann disease within a family. *Muscle and Nerve*, **1993**, 16, 569-70	3.4	9
1	Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. *Journal of Neuroscience Methods*, **1992**, 44, 59-70	3	142